Pediatric investigation review highlights the future of newborn screening with next-generation sequencing

Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the range of conditions that can be identified at birth. Next-generation sequencing is being explored as a complementary screening tool. A review published in Pediatric Investigation examines how next-generation sequencing could expand NBS from single-disease assays to genome-enabled, multi-disease screening approaches.

Every year, millions of newborns undergo routine screening as a preventive strategy to detect inherited disorders before symptoms emerge. Newborn screening (NBS) programs have traditionally relied on biochemical markers to identify specific groups of treatable conditions, achieving remarkable success at a population level. However, as researchers increasingly uncover genetically driven diseases that manifest early in life, questions are emerging about whether existing screening frameworks are adequate for the genomic era.

To bridge this gap in early detection of genetic disease, Dr. Zhelan Huang from the Children’s Hospital of Fudan University, China, and Dr. Wenhao Zhou from Guangzhou Women and Children’s Medical Center have examined the role of next-generation sequencing (NGS) in reshaping the landscape of NBS. Their study, published in Pediatric Investigation on January 6th, 2026, examined the transition of NBS from biochemical assays for a single disease to genome-enabled, multi-disease approaches, while also delving into the challenges that limit the clinical implementation of genomic NBS (gNBS).

Dr. Zhou explains, “Conventional NBS methods are inherently constrained by their reliance on measurable biochemical abnormalities. While effective for disorders like phenylketonuria or congenital hypothyroidism, many genetic diseases do not produce detectable metabolic signals during the neonatal period. Consequently, affected infants appear healthy at birth but develop symptoms after irreversible damage has already occurred.” Genetic screening therefore offers a direct strategy to uncover disease risk at its earliest possible stage.

gNBS uses the NGS technology to analyze DNA obtained from the same dried blood spots already collected for routine screening. Targeted gene panels, whole-exome sequencing, and whole-genome sequencing enable the simultaneous assessment of multiple genes associated with inherited disorders. This genomic approach can substantially expand the benefits of NGS by identifying conditions that are not detectable through traditional biochemical testing.

However, genomic screening introduces new complexities. One of the most significant challenges is interpreting genetic variants of uncertain significance, whose clinical implications remain unclear. Reporting such findings in a population-wide screening program may cause unnecessary parental anxiety and raise ethical concerns. Therefore, gNBS requires careful selection of reportable genes and variants, specifically focusing on those with clinically actionable outcomes during childhood.

While traditional screening methods deliver results within days, genomic sequencing may require weeks. This delay limits its utility for conditions that require immediate intervention. Dr. Zhou adds, “A major research focus is reducing the turnaround time for genetic screening through rapid whole-genome sequencing approaches, which are already being applied in some critically ill infants. Although these approaches are not yet used in routine population screening, continued efforts may broaden their application in the future.”

A major aspect that has been debated since the beginning is the psychological and ethical dimensions surrounding gNBS. Many parents view genomic screening favorably, while healthcare professionals tend to be more cautious, reflecting concerns about data interpretation, consent, and long-term data storage. Another complication that arises is whether to report adult-onset conditions or incidental findings, which highlights the need for clear policy frameworks and access to genetic counseling support.

Dr. Zhou says, “Driven by lower costs, technological advances, and supportive policy frameworks, gNBS is expected to gradually integrate with or even evolve into a standardized tool for newborn healthcare management .” When used along with the conventional assays, it can help clarify ambiguous results and identify conditions beyond the detection limits of conventional methods.

While technical, ethical, and logistical challenges continue to shape its implementation, genomic screening holds the potential to refine the identification and management of inherited diseases from birth. gNBS could enable a more precise and informed approach to newborn care, extending the benefits of screening beyond early diagnosis to support long-term health planning.

***

Reference

Authors: Zhelan Huang¹ and Wenhao Zhou^2,3

Affiliations:        

¹Division of Neonatology, Children’s Hospital of Fudan University, China

²Key Laboratory of Birth Defects, Children’s Hospital of Fudan University, China

³Division of Neonatology and Center for Newborn Care, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, China

About Dr. Wenhao Zhou from Guangzhou Women and Children’s Medical Center, China

Dr. Wenhao Zhou is the President of Guangzhou Women and Children’s Medical Center. Prof. Zhou is a world-renowned practitioner and researcher in neonatology. He has established the China Neonatal Neurocritical Care Alliance and the China Neonatal Genome Project. He is the principal investigator for 15 National Major Research and Development Grants and National Natural Science Foundation of China (NSFC) Key Projects. He is the author of more than 200 peer-reviewed scientific publications.